Compare Amgen, Inc. (AMGN) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs PAGSEG Inc — how do they compare? Amgen, Inc. trades at $417.52 (market cap $224.14B), while PAGSEG Inc trades at $8.65 (market cap $2.48B). The key difference: Amgen, Inc. is far larger — about 90.4× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| AMGN | PAGS | |
|---|---|---|
Market Cap | $224.14B | $2.48B |
Sector | Health | Technology |
52-Week High | $417.20 | $12.00 |
52-Week Low | $271.18 | $8.38 |
Enterprise Value | $267.45B | $10.22B |
Dividend Yield | 2.43% | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
PAGS trades at $8.59, down 5.4% in the last session, with a bearish technical signal despite attractive valuation metrics (P/E 6.17, P/S 0.64). The company reported $20.41B revenue and $2.12B net income for 2025, maintaining stable profitability with a 10.4% net margin. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while analyst consensus remains bullish with a $11.45 price target.
The stock presents a value opportunity given its discounted valuation and strong analyst support (62.5% buy ratings), but faces headwinds from technical weakness and competitive pressures in Brazil's digital banking sector. Upside potential exists if earnings momentum continues, though investors should monitor execution risks and macroeconomic conditions affecting Brazilian financial markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
